Search
Is Less More? Rethinking Salvage Therapy in Pediatric Hodgkin Lymphoma
- OPACC
- Mar 20
- 1 min read
Now, mounting evidence, including findings from three prospective clinical trials, reveal that nontransplant options are an effective second-line treatment for low-risk cHL patients—precluding the need for HDC/ASCT.
Recent Posts
See AllQuality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
While the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...
Коментарі